Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.
Tong X, Patel AS, Kim E, Li H, Chen Y, Li S, Liu S, Dilly J, Kapner KS, Zhang N, Xue Y, Hover L, Mukhopadhyay S, Sherman F, Myndzar K, Sahu P, Gao Y, Li F, Li F, Fang Z, Jin Y, Gao J, Shi M, Sinha S, Chen L, Chen Y, Kheoh T, Yang W, Yanai I, Moreira AL, Velcheti V, Neel BG, Hu L, Christensen JG, Olson P, Gao D, Zhang MQ, Aguirre AJ, Wong KK, Ji H.
Tong X, et al.
Cancer Cell. 2024 Mar 11;42(3):413-428.e7. doi: 10.1016/j.ccell.2024.01.012. Epub 2024 Feb 22.
Cancer Cell. 2024.
PMID: 38402609
Free article.
In lung patients with adenocarcinoma with KRAS(G12C) and STK11/LKB1 co-mutations, we find an enrichment of the squamous cell carcinoma gene signature in pre-treatment biopsies correlates with a poor response to adagrasib. ...
In lung patients with adenocarcinoma with KRAS(G12C) and STK11/LKB1 co-mutations, we find an enrichment of the squamous cell carcinom …